Structure-Guided Design of Cyclic Peptide: A Potent Inhibitor Targeting PD-1/PD-L1 Axis with Antitumor Activity
International Journal of Molecular Sciences · 22.11.2025 · 26 (23) · 11308
DOI: 10.3390/ijms262311308 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.11.2025. Verfasst von Wenyu Peng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Tropical Resources, School of Pharmaceutical Sciences, Hainan University, The Ministry of Education of the People's Republic of Chi…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Peptides, Cyclic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hainan Province, National Natural Science Foundation of China, One Health Cooperative Innovation Center of Hainan University endorsed by Department of Science and Technology of Hainan Province.
Abstract (Originalsprache)
Blocking the protein–protein interaction (PPI) between programmed cell death protein 1 (PD-1) and its ligand PD-L1 is a crucial strategy in cancer immunotherapy. However, existing monoclonal antibody-based therapies have limitations such as high production costs and poor tumor penetration. In this study, we developed a novel cyclic peptide inhibitor, PD-1-0520, through structure-based design. Starting from key fragments of PD-L1 that interact with PD-1, we designed 5 mimetic peptides and further optimized them into 22 cyclic peptide candidates. Through molecular dynamics screening and in vitro and in vivo experimental validation, PD-1-0520 was proven to have potent antitumor activities. Results showed that PD-1-0520 effectively inhibited the PD-1/PD-L1 interaction, restored the immune activity of tumor-infiltrating T cells, and achieved a 68% tumor inhibition rate in B16-F10 tumor-bearing mice without systemic toxicity. It promoted CD8+ T cell infiltration into tumors and upregulated activation markers, remodeling the tumor immune microenvironment. These findings demonstrate that PD-1-0520 is a promising immune checkpoint inhibitor, and our design strategy provides a new approach for developing PPI-targeting bioactive inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Tropical Resources, School of Pharmaceutical Sciences, Hainan University, The Ministry of Education of the People's Republic of China, Haikou 570228, China.
- Laboratory of Biopharmaceuticals and Molecular Pharmacology, One Health Cooperative Innovation Center, Hainan University, Haikou 570228, China.
- Department of Biotechnology, School of Life and Health, Hainan University, Haikou 570228, China.
ORCID-Profile: Yechun Pei, Dayong Wang
Förderung
- Natural Science Foundation of Hainan Province
- National Natural Science Foundation of China
- One Health Cooperative Innovation Center of Hainan University endorsed by Department of Science and Technology of Hainan Province
- Department of Science and Technology of Hainan Province
Zitieren
APA
Peng, W., Gu, W., Chen, W., Zhao, J., Che Ajuyo, N. M., Pei, Y., Min, Y., & Wang, D. (2025). Structure-Guided Design of Cyclic Peptide: A Potent Inhibitor Targeting PD-1/PD-L1 Axis with Antitumor Activity. International Journal of Molecular Sciences, 26(23), 11308. https://doi.org/10.3390/ijms262311308
Vancouver
Peng W, Gu W, Chen W, Zhao J, Che Ajuyo NM, Pei Y, et al. Structure-Guided Design of Cyclic Peptide: A Potent Inhibitor Targeting PD-1/PD-L1 Axis with Antitumor Activity. International Journal of Molecular Sciences. 2025;26(23):11308. doi:10.3390/ijms262311308
BibTeX
@article{Peng2025,
author = {Peng, Wenyu and Gu, Wenyu and Chen, Wujuan and Zhao, Jiazheng and Che Ajuyo, Nuela-Manka'a and Pei, Yechun and Min, Yi and Wang, Dayong},
title = {Structure-Guided Design of Cyclic Peptide: A Potent Inhibitor Targeting PD-1/PD-L1 Axis with Antitumor Activity},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {23},
pages = {11308},
doi = {10.3390/ijms262311308}
}
EUVIMED